
POMDOCTOR LIMITED: shareholders and insiders
Price
$1.61
November 18, 2026
What Ploutos Investor adds for POMDOCTOR
Part of Ploutos Investor, €9.99 a month
- The full history: 3 fiscal years, from 2023
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price was recently adjusted for a split or a spin-off that the company's last filing does not include yet. Market value, P/E, yields and the other figures measured against the price would mix the new shares with the old figures, so we leave them out until the next filing.
- The debt we can read is far below what the company's own annual report says falls due over the coming years, so most of its borrowing is in figures we cannot read. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Sorry, we do not have enough data
for purchases and sales by POMDOCTOR's insiders
Why?
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
No filing over 5%
Since Dec 18, 2024 nobody has filed a Schedule 13D or 13G for POMDOCTOR shares.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | – | – | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 0.04% of its shares outstanding were held short, -13.3% since the report before.
- Shares held short
- 22.5K
- 0.04%
- Since the report before26.0K on Sep 30, 2026
- -13.3%
- under 1
- 62.5K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 11%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 15, 2025: Shares held short 120.1K
- Oct 31, 2025: Shares held short 35.0K
- Nov 14, 2025: Shares held short 102.2K
- Nov 28, 2025: Shares held short 100.5K
- Dec 15, 2025: Shares held short 750.6K
- Dec 31, 2025: Shares held short 428.9K
- Jan 15, 2026: Shares held short 447.8K
- Jan 30, 2026: Shares held short 226.1K
- Feb 13, 2026: Shares held short 210.9K
- Feb 27, 2026: Shares held short 198.6K
- Mar 13, 2026: Shares held short 747.1K
- Mar 31, 2026: Shares held short 229.2K
- Apr 15, 2026: Shares held short 233.5K
- Apr 30, 2026: Shares held short 701.4K
- May 15, 2026: Shares held short 1.22M
- May 29, 2026: Shares held short 581.3K
- Jun 15, 2026: Shares held short 444.4K
- Jun 30, 2026: Shares held short 74.4K
- Jul 15, 2026: Shares held short 24.5K
- Jul 31, 2026: Shares held short 19.0K
- Aug 14, 2026: Shares held short 26.0K
- Aug 31, 2026: Shares held short 19.4K
- Sep 15, 2026: Shares held short 18.3K
- Sep 30, 2026: Shares held short 26.0K
- Oct 15, 2026: Shares held short 22.5K
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading41.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 41.1% of the shares in the reported trades were short sales, against 55.4% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 41.1%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 55.4%
- Change
- -14.3 pts
- Short sales a dayon average, of 100.4K shares
- 41.3K
- More than atof 3,656 US-listed companies, same days
- 22%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 6%
- Oct 13, 2026: Short sales 62.5%
- Oct 14, 2026: Short sales 34.8%
- Oct 15, 2026: Short sales 29.6%
- Oct 16, 2026: Short sales 60.9%
- Oct 19, 2026: Short sales 23.1%
- Oct 20, 2026: Short sales 53.1%
- Oct 21, 2026: Short sales 52%
- Oct 22, 2026: Short sales 50.9%
- Oct 23, 2026: Short sales 35.2%
- Oct 26, 2026: Short sales 47.9%
- Oct 27, 2026: Short sales 63.3%
- Oct 28, 2026: Short sales 58.1%
- Oct 29, 2026: Short sales 49%
- Oct 30, 2026: Short sales 47.3%
- Nov 2, 2026: Short sales 45.1%
- Nov 3, 2026: Short sales 36.4%
- Nov 4, 2026: Short sales 30%
- Nov 5, 2026: Short sales 26.2%
- Nov 6, 2026: Short sales 43.4%
- Nov 9, 2026: Short sales 36.3%
- Nov 10, 2026: Short sales 53.3%
- Nov 11, 2026: Short sales 29.2%
- Nov 12, 2026: Short sales 20.4%
- Nov 13, 2026: Short sales 15.5%
- Nov 16, 2026: Short sales 31.9%
- Nov 17, 2026: Short sales 26%
- Nov 18, 2026: Short sales 48%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q1 2016: Managers 6
- Q4 2025: Managers 8
- Q1 2026: Managers 11
- Q2 2026: Managers 6
Institutional investors by quarter
The fund managers holding POM, quarter by quarter, from Q1 2013 to Q4 2015, 12 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 6 managers held 26.5K shares, worth $38.4K. During the quarter 6 opened a position, 0 closed one, 0 added and 0 trimmed.
The largest holders, Q2 2026
- Citadel Advisors (Griffin)In the quarter
- UBS GroupIn the quarter
- Caitong International Asset ManagementIn the quarter
- Arax Advisory PartnersIn the quarter
- Steward Partners Investment AdvisoryIn the quarter
- Rhumbline AdvisersIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Citadel Advisors (Griffin) | 21.3K | $30.8K | |
| UBS Group | 3,463 | $5.0K | |
| Caitong International Asset Management | 893 | $1.3K | |
| Arax Advisory Partners | 722 | $1.0K | |
| Steward Partners Investment Advisory | 111 | $161 | |
| Rhumbline Advisers | 41 | $60 |
From the SEC's Form 13F data sets, Q1 2016 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do POMDOCTOR's filings show?
Who buys and sells is one part of POMDOCTOR's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have POM's insiders bought or sold?
From – to – POMDOCTOR's insiders reported no purchase or sale of shares on the market.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.